News & Trends - Pharmaceuticals

New TGA restrictions on prescribing hydroxychloroquine for COVID-19

Health Industry Hub | March 25, 2020 |
[Total: 1    Average: 5/5]

Pharma News: In recent days there has been considerable focus on the potential for hydroxychloroquine and the similar compound chloroquine (which is not marketed in Australia) to help in treating COVID-19.

Hydroxychloroquine is used for treatment of malaria and certain autoimmune diseases such as rheumatoid arthritis. Sanofi and Arrotex are among the companies that manufacture this drug.

Recent reports of increased off-label prescribing of medicines containing hydroxychloroquine have raised concerns that this will create a potential shortage of this product in Australia.

Clinical trials are underway around the world examining their potential to treat COVID-19. However, these medicines pose well-known serious risks to patients including cardiac toxicity (potentially leading to sudden heart attacks), irreversible eye damage and severe depletion of blood sugar (potentially leading to coma).

HCP engagement during COVID-19. Health Industry Hub combines expertise in target audience insights, delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.

Given the limited evidence for effect against COVID-19, as well as the risk of significant adverse effects, the TGA strongly discourages the use of hydroxychloroquine outside of its current indications at this time other than in a clinical trial setting or in a controlled environment in the treatment of severely ill patients in hospital.

Prescribing Restrictions

To limit use of hydroxychloroquine to currently approved indications, there have been new restrictions placed on who can initiate therapy using it. Only certain types of specialists will be able to prescribe hydroxychloroquine to new patients (see information for health professionals below).

General practitioners and other medical practitioners (e.g. hospital Resident Medical Officers (RMOS) and doctors in training) can continue to prescribe repeats for hydroxychloroquine to patients in line with the registered indications for patients in whom the medication was prescribed prior to 24 March 2020.

From 24 March 2020, general practitioners and doctors in training can only prescribe these medicines for continued treatment of patients where initial treatment has been authorised by one of the specialists.

There are no medicines that have been approved by the TGA for treatment of COVID-19, therefore prescribing of any medicine for the treatment of COVID-19 is considered off-label use. There is currently no clear data to inform clinical guidance on the use, dosing, or duration for COVID-19 treatment.

To help maintain the supply of hydroxychloroquine in Australia and discourage inappropriate prescribing, effective from 24 March 2020 the TGA is implementing changes to the Poisons Standard to place restrictions on the medical specialists who can initiate prescribing of the medication. Initiation of hydroxychloroquine is restricted to the following medical specialties as per the Medical Board list: dermatology; intensive care medicine; paediatrics and child health; physician; and emergency medicine.

General practitioners and other medical practitioners (e.g. hospital Resident Medical Officers (RMOs) and doctors in training) can continue to prescribe repeats for hydroxychloroquine to patients in line with the registered indications for patients in whom the medication was prescribed prior to 24 March 2020. General practitioners and doctors in training can prescribe these medicines for continued treatment of patients where treatment was previously initiated by one of the specialists.

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - State first heart procedure with non-invasive technology most commonly used to combat cancer

State first heart procedure with non-invasive technology most commonly used to combat cancer

Health Industry Hub | August 4, 2020 |

MedTech News: A team of cardiologists and radiation oncologists from Fiona Stanley Hospital (FSH) and GenesisCare, have become the first […]

More


News & Trends - Pharmaceuticals

Pharma News - Medicines Australia calls for a focus in planning Australia's future in health

Medicines Australia calls for a focus in planning Australia’s future in health

Health Industry Hub | August 4, 2020 |

Pharma News: Medicines Australia Chief Executive Officer, Elizabeth de Somer has urged a focus on planning for the future – […]

More


News & Trends - Medical Technology

MedTech News - Australian-first procedure for chronic pain sufferers

Australian-first procedure for chronic pain sufferers

Health Industry Hub | August 3, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trendsmenu →Medical Technology’ sub-menu.

More


News & Trends - Pharmaceuticals

Pharma News - New PBS listings in lung cancer, epilepsy and ovarian cancer – AstraZeneca, Roche, Pfizer and Emerge Health

New PBS listings in lung cancer, epilepsy and ovarian cancer – AstraZeneca, Roche, Pfizer and Emerge Health

Health Industry Hub | August 3, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trendsmenu →Pharmaceuticals’ sub-menu.

More